177 related articles for article (PubMed ID: 24942375)
1. Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.
Coyne KS; Sexton CC; Thompson C; Bavendam T; Brubaker L
Int Urogynecol J; 2015 Mar; 26(3):373-82. PubMed ID: 24942375
[TBL] [Abstract][Full Text] [Related]
2. Validation of the urgency questionnaire in Portuguese: A new instrument to assess overactive bladder syndrome.
Moraes RP; Silva JLD; Calado AA; Cavalcanti GA
Int Braz J Urol; 2018; 44(2):338-347. PubMed ID: 29219282
[TBL] [Abstract][Full Text] [Related]
3. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder.
Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N
Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200
[TBL] [Abstract][Full Text] [Related]
4. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
[TBL] [Abstract][Full Text] [Related]
7. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
Yüce T; Dökmeci F; Çetinkaya ŞE
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
[TBL] [Abstract][Full Text] [Related]
9. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
10. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
[TBL] [Abstract][Full Text] [Related]
11. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
[TBL] [Abstract][Full Text] [Related]
12. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.
Coyne KS; Thompson CL; Lai JS; Sexton CC
Neurourol Urodyn; 2015 Mar; 34(3):255-63. PubMed ID: 25783168
[TBL] [Abstract][Full Text] [Related]
13. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
[TBL] [Abstract][Full Text] [Related]
14. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
Coyne K; Revicki D; Hunt T; Corey R; Stewart W; Bentkover J; Kurth H; Abrams P
Qual Life Res; 2002 Sep; 11(6):563-74. PubMed ID: 12206577
[TBL] [Abstract][Full Text] [Related]
15. Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ).
Lowenstein L; Rickey L; Kenton K; Fitzgerald MP; Brubaker L; Tulke M; Fordham J; Mueller ER
Int Urogynecol J; 2012 Feb; 23(2):193-6. PubMed ID: 21850507
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
17. The psychometric validation of a 1-week recall period for the OAB-q.
Coyne KS; Gelhorn H; Thompson C; Kopp ZS; Guan Z
Int Urogynecol J; 2011 Dec; 22(12):1555-63. PubMed ID: 21739328
[TBL] [Abstract][Full Text] [Related]
18. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
[TBL] [Abstract][Full Text] [Related]
19. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
20. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
